Efficacy and tolerability of the Subcutaneous Semaglutide for type 2 Diabetes patients: an updated systematic review and meta-analysis.

ABSTRACT:

Objectives

To update and assess the efficacy and tolerability of once weekly subcutaneous semaglutide in patients with type 2 diabetes (T2D).

Materials and methods

PubMed, Science Direct, Cochrane Library, Clinical trial, Springer, OVID, China National Knowledge Infrastructure (CNKI), WanFang Data and China Science and Technology Journal Database (VIP) were searched from inception to January 18, 2023. Randomized controlled trials (RCTs) comparing subcutaneous semaglutide with placebo or any other antidiabetic agent in adults with T2D were eligible. The risk ratio (RR) and mean difference (MD) with 95% confidence intervals (CIs) were determined to synthesize the results.

Results

A total of 17 trials enrolling 14,940 T2D patients were included. For efficacy, compared wi

SUBMITTER: Hu S 

PROVIDER: S-EPMC10612199 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature